RxDoctor Payments Data

Ramon Collazo Bigles, MD

Orthopaedic Surgery · San Juan, PRNPI 1275591570

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (40.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Bsn Medical Inc accounts for 75.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $2,188 and has fallen 93.6% since, to $139 in 2025.

$5,824in general payments, 2019–2025

Across 49 payments — averaging $118.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bsn Medical Inc$4K
  • Smith+Nephew$663
  • Amgen$396
  • Stryker$167
  • Radius Health, Inc.$112
  • Johnson & Johnson$100

What the payments were for

  • Consulting fees$2,01435%
  • Speaking & faculty fees$2,37241%
  • Food & beverage$1,43825%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bsn Medical Inc17$4,386
Smith+Nephew10$663
Amgen12$396
Stryker2$167
Radius Health, Inc.6$112
Johnson & Johnson2$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,824 in reported general payments places this provider in the 70th percentile of 94 orthopaedic surgery providers in Puerto Rico.

See all orthopaedic surgery providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$66,876
Medicare patients
102
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide51$136,940
ForteoTeriparatide16$67,575
Teriparatide13$31,651
ProliaDenosumab11$18,705
XareltoRivaroxaban28$15,753
Diclofenac Potassium58$2,773
Diclofenac Sodium42$1,604
Tramadol Hcl185$844
Alendronate Sodium76$836
Celecoxib45$564
Gabapentin134$496
Colchicine12$221
Triamcinolone Acetonide16$218
Chlorhexidine Gluconate23$205
Mupirocin22$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$112$136,94051 claims
AmgenProlia$396$18,70511 claims
Johnson & JohnsonXarelto$100$15,75328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 94 orthopaedic surgery providers in Puerto Rico.

Other orthopaedic surgery in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →